1
Home
Companies

Nanosonics

Nanosonics
Leadership team

Mr. Michael C. Kavanagh BSc, M.B.A. (CEO, Pres, MD & Exec. Director)

Mr. McGregor Grant BEc, C.A., CA, FCIS, GAICD (CFO & Company Sec.)

Mr. Rod Lopez M.B.A. (Chief Operating Officer)

Products/ Services
Health Care, Information Technology, Manufacturing
Number of Employees
100 - 500
Headquarters
Lane Cove, New South Wales, Australia
Established
2000
Company Registration
SEC CIK number: 0001074769
Net Income
2M - 5M
Revenue
20M - 100M
Traded as
ASX:NAN
URL
https://www.nanosonics.com.au
Overview
Location

Summary
History
Mission
Vision
Key Team
Recognition and Award
References
Summary
Nanosonics Limited, together with its subsidiaries, operates as an infection prevention company in Australia and internationally. The company engages in the manufacturing and distribution of the trophon ultrasound probe disinfector, and its associated consumables and accessories; and research, development, and commercialization of infection control and decontamination products and related technologies. It provides trophon2, an ultrasound probe high level disinfection device; trophon EPR, a low temperature high level disinfection solution for intra-cavity ultrasound probes; and Nanosonics AuditPro, an infection control workflow compliance management solution. Nanosonics Limited was incorporated in 2000 and is headquartered in Macquarie Park, Australia.
History

Nanosonics was founded in 2001 in Sydney Australia. In 2006, Nanosonics listed on ASX and raised approximately AUD$20M in capital funding. In 2007 the company launched the trophon EPR. Subsequently, Nanosonics became a publically listed on the ASX and NASDAQ in 2013.

Mission
Nanosonics is committed to improving patient safety through innovative application of advanced technologies. Our mission is to provide clinicians with effective, cost-efficient and easy-to-use tools to rapidly clean ultrasound probes and improve infection control across healthcare establishments worldwide.
Vision
Nanosonics is dedicated to becoming the world’s leading provider of infection control products for procedures involving ultrasound probes. We believe that our products should be uniquely designed and easy to use in order to help healthcare workers reduce ultrasound-related infections.
Key Team

Dr. Steven Farrugia BE, Ph.D. (Chief Technology Officer)

Mr. David N. Morris (Chief Strategy Officer & Regional Pres Asia Pacific)

Ms. Jodi Sampson (Chief People & Culture Officer)

Matthew Carbines B.Com., L.L.B. (Gen. Counsel)

Mr. Vincent Wang (Head of Global Customer Support & Technical Services)

Mr. Matthew Lipscombe B.E., B.Sc., M.B.A. (Chief Marketing Officer)

Mr. Keith Koby (Sr. VP of Sales - North America)

Recognition and Awards
Nanosonics has won multiple awards, including the Gold Medical Design Award for Innovative Device Design, the Frost & Sullivan Global Technology Innovation Award, and the Frost & Sullivan Healthcare Product Innovation of the Year Award.
References

https://en.wikipedia.org/wiki/Nanosonics

https://in.investing.com/equities/nanosonics

https://finance.yahoo.com/quote/NAN.AX/profile?p=NAN.AX

https://www.crunchbase.com/organization/nanosonics

https://www.nanosonics.com.au

Dive deeper into fresh insights across Business, Industry Leaders and Influencers, Organizations, Education, and Investors for a comprehensive view.

Nanosonics
Leadership team

Mr. Michael C. Kavanagh BSc, M.B.A. (CEO, Pres, MD & Exec. Director)

Mr. McGregor Grant BEc, C.A., CA, FCIS, GAICD (CFO & Company Sec.)

Mr. Rod Lopez M.B.A. (Chief Operating Officer)

Products/ Services
Health Care, Information Technology, Manufacturing
Number of Employees
100 - 500
Headquarters
Lane Cove, New South Wales, Australia
Established
2000
Company Registration
SEC CIK number: 0001074769
Net Income
2M - 5M
Revenue
20M - 100M
Traded as
ASX:NAN
URL
https://www.nanosonics.com.au